Compare Quest Diagnostics Inc (DGX) vs LYFT Inc (LYFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs LYFT Inc — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.06B), while LYFT Inc trades at $16.18 (market cap $5.90B). The key difference: Quest Diagnostics Inc is far larger — about 4.2× LYFT Inc's market cap, and Quest Diagnostics Inc pays a 1.52% dividend while LYFT Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and LYFT Inc for 47 Days on average.
| DGX | LYFT | |
|---|---|---|
Market Cap | $25.06B | $5.90B |
Volume | 927,361 | 9,741,129 |
Sector | Health | Technology |
52-Week High | $247.45 | $24.57 |
52-Week Low | $173.49 | $12.65 |
Typical Hold Time | 56 Days | 47 Days |
Enterprise Value | $30.82B | $5.37B |
Dividend Yield | 1.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
Lyft trades at $16.13, up 2.35% on the day, with a bullish technical signal from moving averages but a neutral stance from oscillators. The company reported strong revenue growth to $6.32B in 2025 and a net income of $2.84B, though recent quarterly EPS results have missed expectations. Positive developments include European expansion and a partnership with Sphere, while a $272.5M legal settlement poses a headwind.
The outlook is mixed; low P/E and P/S ratios suggest undervaluation, and analyst consensus targets $18.07, but execution risks and competitive pressures remain. Earnings consistency is key for sustained upside, with the stock offering value if growth momentum continues despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
